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Serum microRnA in patients 
undergoing atrial fibrillation 
ablation
Marek Kiliszek1*, Karolina Maciak2, Agata Maciejak3, Krystian Krzyżanowski1, 
Robert Wierzbowski1, Monika Gora2, Beata Burzynska2, Agnieszka Segiet4 & 
Andrzej Skrobowski1
MicroRNAs mediate posttranscriptional gene regulation. The aim of the study was to find a microRNA 
predictor of successful atrial fibrillation (AF) ablation. A total of 109 patients undergoing first-time 
AF ablation were included. Nineteen patients were selected to undergo serum microRNA sequencing 
(study group). The sequencing data were used to select several microRNAs that correlated with 12-
month recurrences after AF ablation. Those microRNAs were validated by digital droplet PCR in samples 
from remaining 90 patients. All patients underwent pulmonary vein isolation (RF ablation, contact 
force catheter, electroanatomical system). The endpoint of the study was the 12-month AF recurrence 
rate; the overall recurrence rate was 42.5%. In total, levels of 34 miRNAs were significantly different 
in sera from patients with Af recurrence compared to patients without Af recurrence. Six microRnAs 
(miR-183-5p, miR-182-5p, miR-32-5p, miR-107, miR-574-3p, and miR-144-3p) were validated in the 
whole group. Data from the validation group did not confirm the observations from the study group, 
as no significant differences were found between miRNAs serum levels in patients with and without 
recurrences 12 months after AF ablation.
Atrial fibrillation (AF) is one of the major causes of stroke, heart failure, sudden death, and cardiovascular mor-
bidity in the world and is recognized as an independent factor that increases all-cause mortality. Effective treat-
ment of AF and its symptoms can be attained by AF ablation, also known as pulmonary vein isolation (PVI). The 
major problem with this invasive treatment is that it is associated with a relatively high rate of AF recurrence. 
Several factors that influence the risk of recurrence have been found through laboratory tests and range from 
genetic factors to atrial fibrosis1–3.
A class of gene regulators that may be involved in AF recurrence is microRNAs (miRNAs). These are small 
(20–25 nucleotides long), single-stranded, nonprotein-coding RNAs that function as negative regulators of spe-
cific mRNA targets4. They promote target mRNA degradation and/or inhibit translation by sequence-specific 
base pairing. Accordingly, miRNAs are viewed as regulators of the expression of genes directly or indirectly 
involved in important physiological and pathophysiological processes. One advantage of miRNAs is that they can 
be detected in the circulation, making them attractive as potential biomarkers for the diagnosis and prognosis of 
diverse diseases5.
Our hypothesis in the present study was that serum miRNAs may reflect factors that significantly influence the 
risk of AF recurrence after catheter ablation. The aim of the study was to identify a miRNA predictor of successful 
pulmonary vein isolation in patients with AF.
Results
clinical characteristics of patients. A total of 109 patients was included. The study group consisted of 19 
patients, and the validation group consisted of 90 patients. The characteristics of the study and validation groups 
are shown in Table 1. The one-year recurrence rate was 42.2% (46 patients out of 109), 39% (30/77 patients) in the 
paroxysmal AF subgroup, and 50% (16/32 patients) in the non-paroxysmal AF subgroup.
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Identification of differentially expressed miRNAs by next generation sequencing. A pilot-scale 
study was performed to screen circulating miRNA profiles in patients with recurrent AF (n = 8) and in patients 
with no AF recurrence (n = 11). Levels of serum miRNAs were determined by high-throughput small RNA 
sequencing. An average of 25.8 million reads was obtained per sample. The distribution of mappable reads was 
within the normal range and similar for all samples. The number of identified known miRNAs was 496 with a 
number of counts ≥1 tags per million (TPM) and 270 with ≥10 TPM in all samples.
In total, 34 miRNAs showed significantly altered serum levels in patients with AF recurrence compared to 
patients without AF recurrence (Table 2). Among these, 29 miRNAs were downregulated and 5 miRNAs were 
upregulated. Gene ontology (GO) enrichment analysis was performed to identify GO terms that were signifi-
cantly associated with the target genes of the dysregulated miRNAs. Several biological processes related to the 
pathophysiology of the cardiovascular system were enriched, the most important being regulation of heart mor-
phogenesis (GO:2000826, p = 0,00241), positive regulation of cardiac muscle cell differentiation (GO:2000727, 
p = 0,00522), cardiac conduction (GO:0061337; p = 0,01163), ion membrane transport (GO:0034220, 
p = 0,01257), and regulation of the heart rate by chemical signals (GO:0003062, p = 0,01968).
Validation of selected dysregulated miRnAs using ddpcR. We selected nine candidate miRNAs 
that differentiated the patients with AF recurrence from patients without AF recurrence, based on the statistical 
significance, fold change difference, individual TPM values, and a literature search. The selected miRNAs were 
miR-184, miR-183-5p, miR-182-5p, miR-32-5p, miR-107, miR-574-3p, miR-203a, miR-141-3p, and miR-144-3p. 
The validation was carried out by ddPCR on serum samples of the independent group consisting of patients with 
recurrent AF (n = 38) and patients with no AF recurrence (n = 52).
The miRNAs miR-184, miR-203a, and miR-141-3p were excluded from further analysis due to their very low 
target copy numbers and a lack of positive droplet cluster formation. Consistent with the sequencing data, miR-
32-5p, miR-107, and miR-144-3p were downregulated in sera from patients with AF recurrence compared to 
patients without AF recurrence, but the differences in expression did not reach statistical significance. The results 
of ddPCR validation did not confirm a selective upregulation of miR-574-3p or downregulation of miR-183-5p 
and miR-182-5p (Fig. 1). No statistical significance was observed for miRNA serum levels between patients with 
and without recurrences in the paroxysmal and non-paroxysmal subgroups of AF patients (data not shown). 
Fourteen patients during follow-up underwent one or more re-do procedures, and 6 patients had AF despite 
isolated pulmonary veins. None of the miRNAs tested was significantly different in sera from patients with AF 
recurrences despite isolated pulmonary veins (data not shown).
Discussion
Our aim in this study was to find a miRNA predictor of successful AF ablation (pulmonary vein isolation). In 
the study group, we found several miRNAs whose levels were different in sera from patients with and without 
recurrences 12 months after AF ablation. However, validation of the 90-patient group did not confirm the results.
Several miRNAs has been proposed as biomarkers of AF, but none currently is available for diagnostic pur-
poses6. The data on a link between miRNA and results of AF ablation are scarce. Participants with AF had lower 
plasma levels of miR-21 compared to controls, and miR-21 expression increased 1 month after catheter ablation7. 
The circulating miR-21 level is also associated with AF ablation results in patients with persistent AF undergoing 
ablation (and this level correlates with left atrial low voltage areas)8. Other studies have shown higher levels of 
miRNAs 125a, 10b, 601, 30a-3p, and 199b in patients with 12-month AF recurrences after catheter ablation than 
in patients without AF recurrences9.
Our results suggest that serum miRNAs lack any strong signals with a potential to predict AF ablation results, 
at least in the population consisting primarily of patients with paroxysmal AF. We made every effort to make 
the results reliable. The patient population was, whenever possible, consecutive, and AF ablation was conducted 
Study group 
(n = 19)
Validation 
group (n = 90) p value
Age 63 (58-67) 63 (56-68) 0.97
Women/men 5/14 37/53 0.34
Non-paroxysmal AF 9 (47.4%) 38 (42.2%) 0.88
Hypertension 13 (68.4%) 68 (75.6%) 0.72
Diabetes 6 (31.6%) 17 (18.9%) 0.36
Coronary artery disease 2 (10.5%) 9 (10.0%) 0.73
Left ventricular ejection 
fraction 60 (54-60) 60 (56-65) 0.12
Duration of AF ablation 
(minutes) 127 (16) 127 (24) 0.94
Duration of RF 
applications (seconds) 2395 (533) 2146 (587) 0.09
12 months recurrence 8 (42.1%) 38 (42.2%) 0.81
Table 1. The characteristics of the study and validation groups. Data are shown as median (Q1–Q3) or mean 
(standard deviation) or number (%). Student’s t-test was used for normally distributed variables and the Mann-
Whitney test otherwise. Comparisons of categorical variables were made using chi-square test or Fisher’s exact 
test.
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according to current guidelines10. The patient population in our groups was comparable to that reported in the 
German AF ablation registry and in the EORP AF ablation pilot registry11,12. Our results were comparable to 
those in the German AF ablation registry (the recurrence rate in our study was 42.1% during 1 year of observation 
vs. 45.9% in the German AF ablation registry).
Due to the small size and low abundance of miRNAs in body fluids, miRNA expression profiling is technically 
challenging. For this reason, next generation sequencing (NGS) has recently become a preferred method for 
miRNA profiling13. When compared with the standard quantitative real-time PCR, the NGS platforms are the 
most robust for comprehensive expression profiling of miRNAs and offer the greatest detection sensitivity, the 
largest dynamic range of detection, and the highest accuracy14.
Since ddPCR has demonstrated a high degree of linearity and quantitative correlation in measuring miR-
NAs15, we used this method to confirm the results from our small RNA sequencing experiments. The ddPCR is a 
method based on PCR. It enables a precise quantification of nucleic acids. The digital PCR has capability to obtain 
absolute quantification without external references that gives advantage over classical real-time PCR16.
The majority of patients with AF recurrences after AF ablation showed a reconduction of pulmonary veins 
during a redo procedure. At present, new electrophysiological tools are available (e.g., the Ablation Index) that 
decrease the number of recurrences (and probably, to some extent, the reconductions as well) to less than 10% 
in paroxysmal AF patients17. These results still require large multicenter validation. We were unable to find any 
significant miRNA biomarker in our entire population of patients with AF recurrences; therefore, future studies 
are needed to find predictors of AF recurrence despite the presence of isolated pulmonary veins. These bio-
markers might be important in patient selection and in planning the AF ablation procedure. Our subgroup of 
patients with AF recurrences after AF ablation and isolated pulmonary veins in redo procedures did not show 
miRNAa Sequence Log2FCb p-value
hsa-miR-184 TGGACGGAGAACTGATAAGGGT −2.574 0.00001
hsa-miR-183-5p TATGGCACTGGTAGAATTCACT −0.908 0.00089
hsa-miR-182-5p TTTGGCAATGGTAGAACTCACACT −0.836 0.00271
hsa-miR-484 TCAGGCTCAGTCCCCTCCCGAT −0.700 0.00283
hsa-miR-32-5p TATTGCACATTACTAAGTTGCA −0.619 0.00344
hsa-miR-92b-3p TATTGCACTCGTCCCGGCCTCC −0.674 0.00385
hsa-miR-1224-5p GTGAGGACTCGGGAGGTGG −0.831 0.00412
hsa-miR-92a-3p TATTGCACTTGTCCCGGCCTGT −0.556 0.00488
hsa-miR-451a AAACCGTTACCATTACTGAGTT −0.580 0.00718
hsa-miR-107 AGCAGCATTGTACAGGGCTATCA −0.470 0.00807
hsa-miR-375 TTTGTTCGTTCGGCTCGCGTGA −0.853 0.00880
hsa-miR-574-3p CACGCTCATGCACACACCCACA 0.563 0.00895
hsa-miR-22-3p AAGCTGCCAGTTGAAGAACTGT −0.452 0.01205
hsa-miR-203a GTGAAATGTTTAGGACCACTAG −1.351 0.01459
hsa-miR-548d-5p AAAAGTAATTGTGGTTTTTGCC −0.725 0.01599
hsa-miR-3158-3p AAGGGCTTCCTCTCTGCAGGAC −0.779 0.01651
hsa-miR-551a GCGACCCACTCTTGGTTTCCA 0.815 0.01867
hsa-miR-16-2-3p CCAATATTACTGTGCTGCTTTA −0.581 0.01908
hsa-miR-339-5p TCCCTGTCCTCCAGGAGCTCACG 0.393 0.02031
hsa-miR-141-3p TAACACTGTCTGGTAAAGATGG −0.823 0.02254
hsa-miR-423-5p TGAGGGGCAGAGAGCGAGACTTT −0.376 0.02407
hsa-miR-144-3p TACAGTATAGATGATGTACT −0.672 0.02416
hsa-miR-486-3p CGGGGCAGCTCAGTACAGGAT −0.543 0.02451
hsa-miR-18a-3p ACTGCCCTAAGTGCTCCTTCTGG −0.609 0.02534
hsa-miR-1180-3p TTTCCGGCTCGCGTGGGTGTGT −0.492 0.02569
hsa-miR-1299 TTCTGGAATTCTGTGTGAGGGA −2.055 0.02954
hsa-miR-196b-5p TAGGTAGTTTCCTGTTGTTGGG −0.516 0.03003
hsa-miR-215-5p ATGACCTATGAATTGACAGAC −0.537 0.03117
hsa-miR-1246 AATGGATTTTTGGAGCAGG −0.518 0.04176
hsa-miR-363-3p AATTGCACGGTATCCATCTGTA −0.581 0.04348
hsa-miR-21-5p TAGCTTATCAGACTGATGTTGA −0.369 0.04765
hsa-miR-145-5p GTCCAGTTTTCCCAGGAATCCCT 0.570 0.04905
hsa-miR-326 CCTCTGGGCCCTTCCTCCAG 0.368 0.04910
hsa-miR-1294 TGTGAGGTTGGCATTGTTGTCT −0.512 0.04977
Table 2. Differentially expressed miRNAs obtained by small RNA sequencing in patients with AF recurrence 
compared to those without AF recurrence. amiRNAs selected for subsequent validation are indicated in bold. 
bLogarithm of Fold Change (FC).
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any significant differences in serum levels of the tested miRNAs, but the group was too small (n = 6) to draw any 
reliable conclusions.
Strengths and Limitations
All the clinical procedures (patient qualifications, AF ablation, and follow-up) were performed according to the 
current guidelines. We performed miRNA sequencing in the study group to avoid a priori hypotheses, and valida-
tion was performed with ddPCR, which is one of the best methods available. Nevertheless, this was a single-center 
study with limited number of patients, most of whom showed paroxysmal AF. The miRNA sequencing was 
Figure 1. Serum levels of selected miRNAs validated by ddPCR.Box plots show the levels of miRNAs (in 
copies per microliter of serum). The bottom and top of each box presents the 1st and 3rd quartiles of the data, 
respectively. The median is presented as a solid line across the box. Dots represent outliers. The distribution of 
variables between groups was compared using Student’s t-test for normally distributed variables and the Mann-
Whitney test otherwise. rec 0 -patients without AF recurrence (n = 52); rec 1 - patients with AF recurrence 
(n = 38).
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performed on a small study group (19 patients), and some miRNAs could not be verified due to very low serum 
expression.
In conclusion, our results suggest that the serum miRNA of patients with AF (majorly paroxysmal) does not 
contain any strong signals with the potential to predict AF ablation results.
Materials and Methods
Patients, blood sample collection and serum separation. This was a single-center, prospective study 
(index ablation operations conducted during the period of 2015–2016). Consecutive patients with atrial fibrilla-
tion (paroxysmal and non-paroxysmal) and undergoing their first PVI were enrolled. Exclusion criteria were a 
previous AF ablation and significant inflammatory disease. All patients had symptomatic drug-refractory AF and 
were qualified for PVI according to contemporary guidelines10. All subjects gave their informed consent for inclu-
sion before participation in the study. The study was conducted in accordance with the Declaration of Helsinki, 
and the protocol was approved by the Bioethics Committee of the Military Institute of Medicine.
Blood was collected during venous puncture at the beginning of ablation, and centrifuged after clotting at 
1500 × g for 10 min at room temperature. The resulting serum samples were transferred to cryogenic vials and 
stored at −80 °C until analysis.
The patient group was divided into study and validation groups. Serum samples from patients from the study 
group underwent miRNA sequencing. Candidate miRNAs differentiating the patients with AF recurrence from 
patients without AF recurrence were chosen based on the statistical significance, fold change difference, indi-
vidual TPM values, and a literature search. The selected miRNAs were then validated by digital droplet PCR 
(ddPCR) of the validation group samples.
The primary study endpoint was freedom from recurrence of any atrial tachyarrhythmia (>30 s duration) at 
12 months (after a blanking period of 3 months).
Ablation strategy. The left atrium was accessed through a double transseptal puncture, and a circumferential 
mapping catheter and irrigated contact force catheter were used for mapping and radiofrequency (RF) ablation. 
Fluoroscopy and an electroanatomical CARTO 3 system (Biosense Webster, Diamond Bar, CA, USA) were used 
to navigate the catheters. The temperature limit was 48 °C and the power limit was 30 W (25 W on posterior wall) 
while delivering the RF energy. The ipsilateral veins were isolated jointly. The endpoint of the procedure was isola-
tion of all pulmonary veins. Cardioversion was performed, if needed, to verify the isolation during sinus rhythm. 
Applications other than PVI were performed only if the patient developed atrial tachycardia, typical or atypical 
atrial flutter, or frequent atrial ectopy.
Follow-up. Recurrence of AF was defined as any atrial tachycardia lasting more than 30 s with a three-months 
blanking period applied. All patients were recommended to discontinue antiarrhythmic drugs immediately after 
catheter ablation. The patients were scheduled for two follow-up visits after 6 and 12 months, and all asympto-
matic patients underwent 7-day Holter monitoring (monitoring was not performed in patients with an already 
documented recurrence of AF).
Library preparation, next generation sequencing, and data analysis. Small RNA sequencing 
experiments and data analysis were conducted by Qiagen Genomic Services (Hilden, Germany). RNA was 
extracted from 200 μL serum with the QIAseq miRneasy advanced RNA isolation protocol optimized for serum/
plasma. Total RNA was eluted in ultra-low volume. The library was prepared using the QIAseq miRNA Library 
Kit (Qiagen, Hilden, Germany). A total of 5 µL total RNA was converted into miRNA NGS libraries. Adapters 
containing Unique Molecular Identifiers (UMIs) were ligated to the RNA, and the RNA was then converted to 
cDNA. The cDNA was amplified using PCR (22 cycles) and indices were added during the PCR. The samples were 
purified after the PCR. Library preparations were subjected to quality control using either a Bioanalyzer 2100 or 
TapeStation 4200 system (Agilent Technologies, Santa Clara, CA, USA). The quality of the inserts and the concen-
tration measurements were used to pool the libraries in equimolar ratios. The library pools were quantified using 
the qPCR ExiSEQ LNA Quant kit (Exiqon, Vedbaek, Denmark) and sequenced on the NextSeq. 500 sequencing 
platform (Illumina Inc., San Diego, CA, USA). This yielded 75 nucleotide single-ended reads of good quality (Q 
score greater than 30). Raw data were demultiplexed and FASTQ files for each sample were generated using the 
bcl2fastq software (Illumina Inc.). FASTQ data were checked using the FastQC tool18. The adapters were trimmed 
off as part of the base calling. After filtering of the adapters, the samples had the expected main peak of around 
18–23 nucleotides representing miRNAs. The sequencing reads were mapped to entries in miRBase release 2019.
The supervised analysis of expression levels was performed using the trimmed mean of M-values normaliza-
tion method (TMM normalization) in the EdgeR statistical software package20. The miRNAs were considered to 
be significantly differentially expressed at a cut-off of p-value < 0.05, as estimated by an exact test on the nega-
tive binomial distribution. The Gene Ontology (GO) enrichment analysis was performed using miRSearch21 to 
identify target genes of the differentially expressed miRNAs. The standard Fisher’s test was used to investigate 
enrichment of GO terms between the groups, followed by the ‘Elim’ method incorporating the topology of the 
GO network to compensate for local dependencies between GO, which can mask significant GO terms22.
MiRnA isolation and cDnA synthesis. Total RNA with preserved miRNAs was extracted from 200 μL 
of serum samples using the miRNeasy Serum/Plasma Advanced Kit (Qiagen) in accordance with the manu-
facturer’s protocol. To maximize the yield and reproducibility, 1.25 μg/mL of MS2 bacteriophage RNA carrier 
(Roche Diagnostics, Mannheim, Germany) was added at the beginning of the procedure. For quality control of 
the RNA isolation, three synthetic RNA spike-ins (UniSp2, UniSp4, and UniSp5) from the RNA Spike-in Kit for 
RT (Qiagen) were added to the samples prior to purification at concentrations recommended by the manufac-
turer. The cDNA was synthesized from purified miRNA according to the protocol supplied with the miRCURY 
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LNA RT Kit (Qiagen), with the addition of two spike-ins (UniSp6 and cel-miR-39-3p) intended as a cDNA syn-
thesis control.
Droplet digital pcR. Selected miRNAs were subjected to a subsequent validation step by ddPCR using the 
QX200 Droplet Digital PCR system (Bio-Rad, Hercules, CA, USA). The cDNAs were diluted 10-fold for low-copy 
targets (hsa-miR-182-5p, hsa-miR-183-5p, and hsa-miR-574-3p) or 20-fold for the others, and 9 µL was used in 
each 20 µL of ddPCR reaction using miRCURY LNA miRNA PCR assays (Qiagen) and QX200 ddPCR EvaGreen 
Supermix (Bio-Rad). A no-template control (NTC) was included in every assay. The ddPCR reactions were par-
titioned and emulsified in 70 µL of QX200 Droplet generation oil for EvaGreen in the QX200 Droplet Generator 
(Bio-Rad). The resulting droplets were transferred to a 96-well plate and PCR was performed in the T100 Thermal 
Cycler (Bio-Rad) with the thermal cycling conditions recommended for EvaGreen assays. After amplification, 
the plates were loaded into the QX200 Droplet Reader and the ddPCR results were analyzed with QuantaSoft 
software v.1.7.4.0917 and QuantaSoft Analysis Pro software v.1.0.596 (Bio-Rad). The absolute number of target 
molecules in the ddPCR reaction was determined using Poisson statistical analysis and background-corrected 
based on the NTC. The concentration of target miRNA was further corrected for the input amount of serum, and 
the final results were provided as the number of copies per microliter of serum.
Statistical analysis. Descriptive characteristics reported for continuous variables were medians with 1st 
and 3rd quartiles or mean (standard deviation), depending on normality of distribution of variable. Normality of 
variables distribution was tested using the Shapiro-Wilk test. Group comparisons were made using Student’s t-test 
for normally distributed variables and the Mann-Whitney test otherwise. Categorical variables were presented 
as frequencies, group comparisons were made using chi-square test or Fisher’s exact test. For all calculations, 
2-tailed tests were used, and the level of significance was set at 0.05.
Statistical power of the study. Assuming a standard deviation of miRNA of about 50% of the mean value of 
that miRNA, we were able to detect a 1.3 fold change or greater with 80% power at the level of significance 0.05.
Statistical analysis was performed with Statistica v. 12 (Statsoft Inc., Tulsa, Oklahoma, United States) and R 
statistical software, version 3.4.023.
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